Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...